Prescription Drug Use in Pregnancy: A Retrospective, Population-Based Study in British Columbia, Canada (2001-2006)

Clinical Therapeutics

Volumn 34, Issue 1, 2012, Pages

  Daw, Jamie R ^a   Mintzes, Barbara ^a   Law, Michael R ^a   Hanley, Gillian E ^a   Morgan, Steven G ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Data linkage; Pregnancy; Prescription drugs; Teratogens

Indexed keywords

ACICLOVIR; AMOXICILLIN; ANTIDEPRESSANT AGENT; BENZODIAZEPINE; BETAMETHASONE; CEFALEXIN; CODEINE; DOXYLAMINE; ERYTHROMYCIN; FLUTICASONE; FOLIC ACID; HYDROCORTISONE; INSULIN; IRON; LEVOTHYROXINE; LORAZEPAM; METRONIDAZOLE; MOMETASONE FUROATE; MULTIVITAMIN; NITROFURANTOIN; ORAL CONTRACEPTIVE AGENT; OXAZEPAM; PAROXETINE; PENICILLIN V; PRESCRIPTION DRUG; PROGESTERONE; RANITIDINE; SALBUTAMOL; SULFAMETHOXAZOLE;

ADULT; ARTICLE; CANADA; DEMOGRAPHY; DRUG USE; FEMALE; FIRST TRIMESTER PREGNANCY; FOOD AND DRUG ADMINISTRATION; HEALTH CARE; HEALTH STATUS; HUMAN; LIVE BIRTH; MAJOR CLINICAL STUDY; MATERNAL CARE; MEDICAL RECORD; OVULATION INDUCTION; PATIENT COMPLIANCE; POPULATION RESEARCH; PRENATAL CARE; PUERPERIUM; RETROSPECTIVE STUDY; RISK BENEFIT ANALYSIS;

EID: 84856159520     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2011.11.025     Document Type: Article

References (31)

1. Frederiksen M.C. The drug development process and the pregnant woman. J Midwifery Womens Health 2002, 47:422-425.
2. Daw J.R., Hanley G.E., Greyson D.L., Morgan S.G. Prescription drug use during pregnancy in developed countries: a systematic review. Pharmacoepidemiol Drug Saf 2011, 20:895-902.
3. Olesen C., Steffensen F., Nielsen G., et al. Drug use in first pregnancy and lactation: a population-based survey among Danish women. The EUROMAP group. Eur J Clin Pharmacol 1999, 55:139-144.
4. Malm H., Martikainen J., Klaukka T., Neuvonen P.J. Prescription drugs during pregnancy and lactation-a Finnish register-based study. Eur J Clin Pharmacol 2003, 59:127-133.
5. Lacroix I., Hurault C., Sarramon M., et al. Prescription of drugs during pregnancy: a study using EFEMERIS, the new French database. Eur J Clin Pharmacol 2009, 65:839-846.
6. Egen-Lappe V., Hasford J. Drug prescription in pregnancy: analysis of a large statutory sickness fund population. Eur J Clin Pharmacol 2004, 60:659-666.
7. Garriguet D. Medication use among pregnant women. Health Rep 2006, 17:9-18.
8. Andrade S., Gurwitz J., Davis R., et al. Prescription drug use in pregnancy. Am J Obstet Gynecol 2004, 191:398-407.
9. Riley E., Fuentes-Afflick E., Jackson R., et al. Correlates of prescription drug use during pregnancy. J Womens Health 2005, 14:401-409.
10. Rubin J., Ferencz C., Loffredo C. Use of prescription and non-prescription drugs in pregnancy. J Clin Epidemiol 1993, 46:581-589. Baltimore-Washington Infant Study Group.
11. Kulaga S., Zargarzadeh A., Berard A. Prescriptions filled during pregnancy for drugs with the potential of fetal harm. Br J Obstet Gynecol 2009, 116:1788-1795.
12. Wen S., Yang T., Krewski D., et al. Patterns of pregnancy exposure to prescription FDA C, D and X drugs in a Canadian population. J Perinatol 2008, 28:324-329.
13. Splinter M., Sagraves R., Nightengale B., Rayburn W.F. Prenatal use of medications by women giving birth at a university hospital. Southern Med J 1997, 90:498-502.
14. Cooper W., Hickson G., Ray W. Prescriptions for contraindicated category X drugs in pregnancy among women enrolled in TennCare. Paediatr Perinatal Epidemiol 2004, 18:106-111.
15. Anatomical Therapeutic Classification: Structure and Principles World Health Organization, Accessed January 15, 2010. http://www.whocc.no/atc/structure_and_principles/.
16. Content and format of labeling for human prescription drug and biological products; requirements for pregnancy and lactation labeling. Fed Reg 2008, 73:30832-30833. US Food and Drug Administration.
17. Wilson R. Principles of human teratology: drug, chemical and infectious exposure. SOGC Clinical Practice Guideline. J Obstet Gynaecol Can 2007, 29:911-917.
18. Repchinsky C.A. Drug use in pregnancy: resources and recommendations. Can Fam Physician 2010, 56:634.
19. Addis A., Sharabi S., Bonati M. Risk classification systems for drug use during pregnancy: are they a reliable source of information?. Drug Saf 2000, 23:245-253.
20. Pregnancy and Lactation Labeling US Food and Drug Administration, Accessed September 1, 2011. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/Labeling/ucm093307.htm.
21. Olesen C., Thrane N., Henriksen T., et al. Associations between socio-economic factors and the use of prescription medication during pregnancy: a population-based study among 19,874 Danish women. Eur J Clin Pharmacol 2006, 62:547-553.
22. Gagne J., Maio V., Berghella V., et al. Prescription drug use during pregnancy: a population-based study in Regione Emilia-Romagna, Italy. Eur J Clin Pharmacol 2008, 64:1125-1132.
23. Hansen W., Peacock A., Yankowitz J. Safe prescribing practices in pregnancy and lactation. J Midwifery Womens Health 2002, 47:409-421.
24. Schwarz E.B., Postlethwaite D.A., Hung Y.Y., Armstrong M.A. Documentation of contraception and pregnancy when prescribing potentially teratogenic medications for reproductive-age women. Ann Intern Med 2007, 147:370-376.
25. Calderon-Margalit R., Qiu C., Ornoy A., et al. Risk of preterm delivery and other adverse perinatal outcomes in relation to maternal use of psychotropic medications during pregnancy. Am J Obstet Gynecol 2009, 201:e579.
26. Wikner B.N., Stiller C.O., Bergman U., et al. Use of benzodiazepines and benzodiazepine receptor agonists during pregnancy: neonatal outcome and congenital malformations. Pharmacoepidemiol Drug Saf 2007, 16:1203-1210.
27. Briggs G., Freeman K., Yaffe S. Drugs in Pregnancy and Lactation 2008, Lippincott, Williams and Wilkins, Philadelphia.
28. Raebel M., Ellis J., Andrade S. Evaluation of gestational age and admission date assumptions used to determine prenatal drug exposure from administrative data. Pharmacoepidemiol Drug Saf 2005, 14:829-836.
29. Doering P., Boothby L., Cheok M. Review of pregnancy labeling of prescription drugs: is the current system adequate to inform of risks?. Am J Obstet Gynecol 2002, 187:333-339.
30. Sannerstedt R., Lundborg P., Danielsson B., et al. Drugs during pregnancy: an issue of risk classification and information to prescribers. Drug Saf 1996, 14:69-77.
31. Feibus K. FDA's proposed rule for pregnancy and lactation labeling: improving maternal child health through well-informed medicine use. J Med Toxicol 2008, 4:284-288.